Display options
Cite
Zhao QT, Yang ZX, Yang L, et al. Diagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysis. Int J Clin Exp Med. 2015;8(10):17271-80
Zhao, Q. T., Yang, Z. X., Yang, L., Xing, D., Wei, J. C., & Li, W. Y. (2015). Diagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysis. International journal of clinical and experimental medicine, 8(10), 17271-80.
Zhao, Qing-Tao, et al. "Diagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysis." International journal of clinical and experimental medicine vol. 8,10 (2015): 17271-80.
Zhao QT, Yang ZX, Yang L, Xing D, Wei JC, Li WY. Diagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysis. Int J Clin Exp Med. 2015 Oct 15;8(10):17271-80. eCollection 2015. PMID: 26770319; PMCID: PMC4694219.
Copy Download .nbib Format: NLM
Share it on

Int J Clin Exp Med. 2015 Oct 15;8(10):17271-80. eCollection 2015.

Diagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysis.

International journal of clinical and experimental medicine

Qing-Tao Zhao, Zhao-Xu Yang, Lei Yang, Dong Xing, Jing-Chao Wei, Wen-Yi Li

Affiliations

  1. Department of Thoracic Surgery, Hebei General Hospital Shijiazhuang 050051, Hebei, P. R. China.
  2. Department of Orthopedics, Hebei General Hospital Shijiazhuang 050051, Hebei, P. R. China.
  3. Department of Pediatrics, Bethune International Peace Hospital of Chinese PLA Shijiazhuang 050082, Hebei, P. R. China.

PMID: 26770319 PMCID: PMC4694219

Abstract

UNLABELLED: Aim and Backgrounds: The accurate diagnosis of lung carcinoma patients with bone metastases is crucial for therapy and the prevention of complications. We performed a systematic review and meta-analysis to evaluate the diagnostic value of serum bone-specific alkaline phosphatase (BALP) in lung carcinoma patients with bone metastases.

METHODS: Such databases as PubMed, Embase, Cochrane Library, Web of Science, Ovid, BioMed Central, Biosis previews and four Chinese databases (Chinese Biomedical Literature Database-disc (CBM), Chinese National Knowledge Infrastructure (CNKI), Technology of Chongqing (VIP) and Wan Fang DATA) were retrieved on computer, and the relevant journals were also manually searched to collect the trials on BALP in diagnosis of lung carcinoma patients with bone metastases. The meta-analysis was conducted by using Meta-Disc 1.4 software.

RESULTS: A total of 8 studies were included, and there were 848 lung carcinoma patients diagnosed by gold standard, patients were divided into two groups: 419 cases with bone metastases and 429 cases without bone metastases. The meta-analysis showed that, the pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR) was 0.48 [95% CI (0.43 to 0.53)], 0.86 [95% CI (0.82 to 0.89)], 3.14 [95% CI (2.47 to 3.99)], 0.62 [95% CI (0.56 to 0.68)], 6.66 [95% CI (4.62 to 9.60)] respectively. And the AUC of SROC was 0.78, (Q*=0.72).

CONCLUSION: BALP has greater diagnostic value in detecting lung carcinoma patients with bone metastases. However, further large scale studies are required to confirm the predictive value.

Keywords: BALP; Lung carcinoma; bone metastases; meta-analysis

References

  1. Chest. 2003 Jan;123(1 Suppl):137S-146S - PubMed
  2. J Korean Med Sci. 2009 Apr;24(2):275-80 - PubMed
  3. Asian Pac J Cancer Prev. 2012;13(9):4331-4 - PubMed
  4. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):32-8 - PubMed
  5. Cell Res. 2005 Jan;15(1):57-62 - PubMed
  6. Clin Biochem. 2002 Jun;35(4):293-6 - PubMed
  7. Future Oncol. 2011 Nov;7(11):1285-97 - PubMed
  8. Cancer Treat Rev. 2008 Nov;34(7):629-39 - PubMed
  9. Clin Lung Cancer. 2011 Nov;12(6):341-9 - PubMed
  10. Ann Intern Med. 2008 Dec 16;149(12):889-97 - PubMed
  11. Asian Pac J Cancer Prev. 2013;14 (6):3647-52 - PubMed
  12. J Clin Epidemiol. 2003 Nov;56(11):1129-35 - PubMed
  13. Zhongguo Fei Ai Za Zhi. 2014 Feb;17(2):57-72 - PubMed
  14. Int J Clin Oncol. 2012 Apr;17(2):112-8 - PubMed
  15. Lancet. 2013 Aug 24;382(9893):709-19 - PubMed
  16. Ann Intern Med. 2011 Oct 18;155(8):529-36 - PubMed
  17. Med Oncol. 2010 Jun;27(2):332-8 - PubMed
  18. Eur J Radiol. 2010 Apr;74(1):231-5 - PubMed
  19. Int J Biol Markers. 2007 Jul-Sep;22(3):214-20 - PubMed
  20. Cancer Epidemiol. 2012 Feb;36(1):94-8 - PubMed
  21. Br J Cancer. 1997;76(6):760-4 - PubMed
  22. Int J Clin Exp Med. 2014 Nov 15;7(11):4000-7 - PubMed
  23. Zhongguo Fei Ai Za Zhi. 2010 Oct;13(10):947-53 - PubMed
  24. Lung Cancer. 2009 Sep;65(3):333-8 - PubMed
  25. Q J Nucl Med Mol Imaging. 2011 Aug;55(4):374-410 - PubMed
  26. Lancet. 2013 Aug 24;382(9893):720-31 - PubMed
  27. J Natl Cancer Inst. 2005 Jan 5;97(1):59-69 - PubMed
  28. Anticancer Res. 2011 Nov;31(11):3879-81 - PubMed
  29. Stat Med. 2002 May 15;21(9):1237-56 - PubMed
  30. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s - PubMed
  31. Int J Clin Exp Med. 2015 Feb 15;8(2):1703-14 - PubMed
  32. Recent Results Cancer Res. 2012;192:197-223 - PubMed
  33. Lung Cancer. 2007 Aug;57(2):229-32 - PubMed
  34. J Man Manip Ther. 2007;15(2):93-102 - PubMed
  35. Lung Cancer. 2011 Jan;71(1):89-93 - PubMed
  36. J Natl Med Assoc. 2008 Apr;100(4):425-8 - PubMed
  37. Clin Chim Acta. 2013 Nov 15;426:102-7 - PubMed
  38. Eur J Cardiothorac Surg. 2010 Apr;37(4):792-6 - PubMed
  39. Radiat Oncol. 2013 Aug 13;8(1):200 - PubMed
  40. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  41. Ann Thorac Surg. 2005 Jan;79(1):16-20 - PubMed
  42. Anticancer Res. 2004 Sep-Oct;24(5B):3193-201 - PubMed
  43. Nat Rev Endocrinol. 2011 Apr;7(4):208-18 - PubMed
  44. Lancet. 2009 Aug 22;374(9690):609-19 - PubMed
  45. Ann Clin Biochem. 2001 Sep;38(Pt 5):572 - PubMed

Publication Types